Last reviewed · How we verify

NCT06025760

Evaluation of Diaphragmatic Function and Quadriceps Muscle Thickness in Patients Receiving High Protein Nutrition

Status unknown NA Last updated 14 September 2023
What this trial tests

NA trial testing patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness in ICU Acquired Weakness in 32 participants. Status unknown.

Timeline
1 October 2023
Primary endpoint
1 October 2024
1 November 2024

Quick facts

Lead sponsorZagazig University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment32
Start date1 October 2023
Primary completion1 October 2024
Estimated completion1 November 2024

Drugs / interventions tested

Conditions studied

Sponsor

Zagazig University

Who can join

Adults 18 to 60, any sex, with ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Different Protein Doses' Effect on Diaphragmatic Function and Quadriceps Thickness

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ICU Acquired Weakness

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing